Home / Health / New Hope for Advanced Blood Cancer Patients
New Hope for Advanced Blood Cancer Patients
25 Aug
Summary
- A clinical trial combines two FDA-approved medications for advanced blood cancer.
- Patients with Myelofibrosis show dramatic symptom improvement in the trial.
- The experimental therapy aims to manage cancer symptoms, not cure it.
A phase one clinical trial conducted in Philadelphia is providing renewed hope for patients diagnosed with an advanced form of blood cancer. This experimental treatment is specifically designed for individuals suffering from Myelofibrosis who have found little success with conventional therapies.
The trial, taking place at Temple University's Fox Chase Cancer Center, involves a novel combination of two medications that have already received FDA approval for other conditions. This innovative approach targets the overproduction of blood cells, a hallmark of the disease.
One participant, Demetria Mears, who has been living with Myelofibrosis for over a decade, reported a remarkable transformation. She stated that her symptoms have improved dramatically since starting the experimental therapy, leading her to feel "1,000% better."
Dr. Peter Abdelmessieh, a specialist involved in the trial, explained that the primary goal is to reduce patient symptoms by at least 50%. While this therapy is not considered a cure, it offers a promising avenue for managing the disease and alleviating its most severe impacts.
